Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biofrontera (BFRI) EPS (Weighted Average and Diluted) (2021 - 2025)

Biofrontera has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at $0.63 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 270.59% year-over-year to $0.63; the TTM value through Dec 2025 reached -$1.03, up 72.46%, while the annual FY2025 figure was -$1.04, 67.7% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.63 at Biofrontera, up from -$0.62 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $4.55 in Q4 2023 and troughed at -$7.23 in Q2 2023.
  • A 5-year average of -$1.1 and a median of -$0.57 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 270.59% in 2025 and fell as far as 1040.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$2.0 in 2021, then tumbled by 40.0% to -$2.8 in 2022, then surged by 262.5% to $4.55 in 2023, then tumbled by 96.26% to $0.17 in 2024, then soared by 270.59% to $0.63 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BFRI at $0.63 in Q4 2025, -$0.62 in Q3 2025, and -$0.57 in Q2 2025.